Gilead Sciences: Colorectal Neoplasms trials

The registry lists 10 Colorectal Neoplasms studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 7Phase 2 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)TerminatedNCT05330429Phase 2Results posted
• Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal CancerCompletedNCT02953782Phase 1/2Results posted
• Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal AdenocarcinomaTerminatedNCT01479465Phase 2Results posted
• A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal CancerWithdrawnNCT01915472Phase 2
• Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal CancerTerminatedNCT01605318Phase 1/2
• Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal CancerWithdrawnNCT01273402Phase 1
• Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal CancerCompletedNCT01270698Phase 1
• Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After SurgeryTerminatedNCT00041691Phase 1
• Safety Study of hMN14 to Treat Either Colorectal or Breast CancerCompletedNCT00041652Phase 1/2
• Safety Study of 90Y-hMN14 to Treat Colorectal CancerCompletedNCT00040599Phase 1/2